- Home
- NOTV vs FBRX Comparison
NOTV vs FBRX Comparison
Compare NOTV & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- FBRX
- Stock Information
- Founded
- NOTV 1974
- FBRX N/A
- Country
- NOTV United States
- FBRX United States
- Employees
- NOTV N/A
- FBRX N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- NOTV Health Care
- FBRX Health Care
- Exchange
- NOTV Nasdaq
- FBRX Nasdaq
- Market Cap
- NOTV 62.5M
- FBRX 69.7M
- IPO Year
- NOTV 1997
- FBRX N/A
- Fundamental
- Price
- NOTV $2.00
- FBRX $10.55
- Analyst Decision
- NOTV Strong Buy
- FBRX Strong Buy
- Analyst Count
- NOTV 1
- FBRX 2
- Target Price
- NOTV $5.00
- FBRX $61.00
- AVG Volume (30 Days)
- NOTV 512.6K
- FBRX 185.0K
- Earning Date
- NOTV 08-07-2025
- FBRX 08-13-2025
- Dividend Yield
- NOTV N/A
- FBRX N/A
- EPS Growth
- NOTV N/A
- FBRX N/A
- EPS
- NOTV N/A
- FBRX N/A
- Revenue
- NOTV $480,402,000.00
- FBRX N/A
- Revenue This Year
- NOTV $4.99
- FBRX N/A
- Revenue Next Year
- NOTV $5.39
- FBRX N/A
- P/E Ratio
- NOTV N/A
- FBRX N/A
- Revenue Growth
- NOTV N/A
- FBRX N/A
- 52 Week Low
- NOTV $1.15
- FBRX $4.11
- 52 Week High
- NOTV $6.48
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- NOTV 49.04
- FBRX 44.73
- Support Level
- NOTV $2.06
- FBRX $10.15
- Resistance Level
- NOTV $2.30
- FBRX $13.20
- Average True Range (ATR)
- NOTV 0.17
- FBRX 1.89
- MACD
- NOTV 0.02
- FBRX -0.38
- Stochastic Oscillator
- NOTV 70.31
- FBRX 4.72
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).